Syndax Pharmaceuticals.
business
- Reports this week
- 0
- Active events
- 0
- Connections
- 31
What's happening
Earlier this month
One to three months ago
-
Shares of Syndax Pharmaceuticals were traded on the Nasdaq stock exchange on August 12, 2026.Some support2 reports
-
Syndax Pharmaceuticals confirms Michael Metzger as CEO and Botwood as Chief Medical Officer.Some support2 reports
-
CEO Michael Metzger sold shares of Syndax Pharmaceuticals stock.Some support1 report
Gone quiet
No new reports in 90+ days-
Syndax Pharmaceuticals presented data at EHA Congress and is seeking successful regulatory approval for its drug pipeline.Some support1 report
-
Trump's pledge to unleash oil and gas benefits US stocks, specifically impacting Syndax Pharmaceuticals.Some support1 report
-
On June 25, 2025, the FDA approved revumenib for acute leukemia, and data was presented at the EHA Congress in Milan.Speculative1 report1 development inside
-
FDA granted Priority Review for Syndax's sNDA on June 25, 2025.Speculative2 reports
-
Syndax Pharmaceuticals has FDA-approved therapies in its pipeline and uses LinkedIn for company communication.Some support7 reports1 development inside
-
Syndax Pharmaceuticals' stock price moved following changes in earnings estimates, prompting institutional investors to calculate fair value.Some support1 report
-
Syndax Pharmaceuticals reported collaboration revenue derived from Niktimvo sales.Some support1 report
-
FDA approval of Revuforj is key catalyst for Syndax Pharmaceuticals.Some support3 reports
-
Analysts set price targets for Syndax Pharmaceuticals stock on September 1, 2025.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Syndax Pharmaceuticals this week
News at the entities that move Syndax Pharmaceuticals most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Syndax Pharmaceuticals
-
Incyte OperationalIncyte, a biotech company based in Wilmington, outperformed the biotech ETF.Moves Syndax Pharmaceuticals
-
AbbVie OperationalAbbVie and Cerevel Therapeutics successfully launched a new drug for Parkinson's disease, pending government coverage negotiations.Moves Syndax Pharmaceuticals
-
Nasdaq StructuralApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Syndax Pharmaceuticals
-
Milan Shared contextGiambattista Valli regained full ownership of his brand and established standalone stores in Milan.Moves Syndax Pharmaceuticals
-
Stockholm Shared contextHemnet, Sweden's largest property portal, is based in Stockholm.Moves Syndax Pharmaceuticals
Connections
The 11 strongest of 31, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA regulates Syndax Pharmaceuticals, granting approvals and priority reviews for its therapeutic pipeline.
-
Nasdaq Structural
Syndax Pharmaceuticals is a company whose shares are listed and traded on the Nasdaq stock exchange.
-
Botwood Structural
Botwood serves as the chief medical officer for Syndax Pharmaceuticals.
-
Incyte Operational
Syndax and Incyte are co-commercializing the drug Niktimvo, with Syndax receiving collaboration revenue from sales.
-
Michael Metzger Structural
Michael Metzger serves as the Chief Executive Officer of Syndax Pharmaceuticals.
-
AbbVie Operational
The two companies are actively competing against each other within the specialized healthcare and biopharma market.
-
Milan Shared context
Syndax Pharmaceuticals presents scientific data at the EHA Congress held in Milan.
-
LinkedIn Mentioned together
Syndax Pharmaceuticals utilizes LinkedIn as a professional platform to disseminate company news and updates.
Show all 11 connections
-
Stockholm Shared context
Syndax Pharmaceuticals is located in Stockholm, where it presented data at EHA Congress.
-
MarketBeat Mentioned together
MarketBeat provides analyst ratings and financial information regarding Syndax Pharmaceuticals.
-
Italy Shared context
Syndax Pharmaceuticals operates within the geographical context of Italy for scientific congresses.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
1 eventJuly 2026
2 eventsShow 1 earlier month
June 2026
9 events- Syndax Pharmaceuticals presented data at EHA Congress and is seeking successful regulatory approval for its drug pipeline.
- Trump's pledge to unleash oil and gas benefits US stocks, specifically impacting Syndax Pharmaceuticals.
- On June 25, 2025, the FDA approved revumenib for acute leukemia, and data was presented at the EHA Congress in Milan.
- FDA granted Priority Review for Syndax's sNDA on June 25, 2025.
- Syndax Pharmaceuticals has FDA-approved therapies in its pipeline and uses LinkedIn for company communication.
- Syndax Pharmaceuticals' stock price moved following changes in earnings estimates, prompting institutional investors to calculate fair value.
- Syndax Pharmaceuticals reported collaboration revenue derived from Niktimvo sales.
- FDA approval of Revuforj is key catalyst for Syndax Pharmaceuticals.
- Analysts set price targets for Syndax Pharmaceuticals stock on September 1, 2025.